Next Thursday's event brings together four diverse companies all with something in common - huge potential.
Ebiquity (LON:EBQ), Rex Bionics (LON:RXB), Challenger Acquisitions (LON:CHAL) & Deltex Medical (LON:DEMG) have plenty of newsworthy developments to update us on.
Make sure you don’t miss out on November 5 by registering to attend HERE.
Ebiquity collects, aggregates and analyses vast amounts of data to inform its 1100 clients how best to maximise the return from their marketing spend. The company is very well placed to capitalise in a world where companies are now demanding greater accountability from advertising investments.
The company recently announced that it has appointed Michael Karg, CEO at Razorfish International, as its new Chief Executive - a move which will be effective from the beginning of 2016. Nick Manning, Chief Strategy Officer, will be at the forum to update investors on the company's future plans for growth.
Also presenting is Rex Bionics, the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. The company recently announced that it generated its maiden sales in recent months as the reputation of its flagship product continues to gain momentum.
The news follows British High Court settlements which awarded funding for the purchase of a REX robotic device and associated physiotherapy. Chief Executive Crispin Simon will be on hand to bring investors up to date on developments at Rex Bionics since the company last presented with us back in April.
Elsewhere, Challenger Acquisitions is an investment vehicle with a focus on investments in tourist attractions, specifically giant observation wheels. Earlier this year, the company signed a deal with Starneth which will give the group access to projects such as the Dubai-I wheel and the New York Wheel.
The company is run by Mark Gustafson who has a track record of raising funds for Oil and Gas Projects. However, the Challenger Acquisitions CEO argues that this space is more of a recession-proof area to invest in. Mark Gustafson will outline the company's plans for growth over the next 12-18 months.
Last but not least, Deltex Medical manufactures and markets haemodynamic monitoring technologies - products which measure blood flow in the central circulation in real time. It is currently on track to have 30 accounts that are using at least 100 probes per month by the middle of 2016.
The company recently boasted that its shift to fast growing international markets is starting to bear fruits with its US revenues growing by 28% over the first half of 2015. CEO Ewan Phillips will be here to outline the investment proposition in much more detail.
Please Join us at 5:45pm to get yourself a seat and to allow for a prompt 6:00pm start. Each company has approximately 20 minutes to give a short presentation, followed by 10 minutes of Q&A. The evening will end with a complimentary bar and canapes, giving you the opportunity to speak with the directors and other investors.